What is the recommended management of hyperthyroidism in adults, including initial antithyroid drug selection, beta‑blocker use, monitoring, and definitive treatment options?

Management of Hyperthyroidism

Methimazole should be the initial antithyroid drug for virtually all adults with Graves' disease, started at 10-20 mg daily and titrated to maintenance doses of 5-10 mg daily, with beta-blockers added for symptomatic control in elderly patients, those with heart rates >90 bpm, or cardiovascular disease. 1

Initial Evaluation and Diagnosis

When thyrotoxicosis is suspected but not clearly Graves' disease, obtain a radioactive iodine uptake test; add a thyroid scan if nodules are present 1. This distinguishes Graves' disease from toxic multinodular goiter, toxic adenoma, or destructive thyroiditis—critical for selecting appropriate therapy.

Symptomatic Management with Beta-Blockers

Beta-adrenergic blockade is mandatory for:

• Elderly patients with symptomatic thyrotoxicosis 1
• Any patient with resting heart rate >90 bpm 1
• Patients with coexistent cardiovascular disease 1

Consider beta-blockers for all symptomatic patients to control tachycardia, anxiety, and tremor 1. This addresses morbidity and quality of life immediately while definitive treatment takes effect.

Definitive Treatment Options for Graves' Disease

Three equally acceptable modalities exist: radioactive iodine (RAI), antithyroid drugs (ATDs), or thyroidectomy 1. Selection depends on patient factors and preferences.

Antithyroid Drug Therapy (First-Line for Many Patients)

Methimazole is superior to propylthiouracil except in three specific situations 1:

1. First trimester of pregnancy (use PTU)
2. Thyroid storm
3. Minor reactions to methimazole when patient refuses RAI/surgery

Dosing algorithm:

• Initial: 10-20 mg methimazole daily (higher doses for severe disease) 1
• Maintenance: Titrate to 5-10 mg daily once euthyroid 1
• Duration: Continue 12-18 months, then taper if TSH normalized 1

Critical safety monitoring:

Before starting ATDs, obtain baseline CBC with differential and liver function tests (bilirubin, transaminases) 1. Do not perform routine monitoring of white blood counts during treatment 1.

Patient must immediately stop medication and contact physician for:

• Fever or pharyngitis (agranulocytosis risk—obtain urgent CBC with differential) 1
• Jaundice, light-colored stools, dark urine (hepatotoxicity) 1
• Pruritic rash, arthralgias, abdominal pain, nausea, fatigue 1

Common pitfall: Agranulocytosis occurs suddenly and cannot be prevented by routine monitoring—patient education about symptoms is paramount 1.

Predicting remission: Measure TSH receptor antibodies (TRAb) before stopping ATDs at 12-18 months; normal levels predict higher remission rates 1. If hyperthyroidism recurs after completing a course, strongly consider RAI or surgery rather than prolonged ATD therapy 1.

Radioactive Iodine Therapy

Preparation for RAI:

• High-risk patients (extremely symptomatic, free T4 2-3× upper limit, elderly, cardiovascular disease) require beta-blockers before RAI 1
• Consider methimazole pretreatment in these high-risk patients, though one guideline author dissented on necessity 1
• Optimize all comorbid conditions before administering RAI 1
• Mandatory pregnancy test within 48 hours before treatment in women of childbearing potential 1

Dosing: Administer sufficient radiation in a single dose (typically 10-15 mCi) to render patient hypothyroid—this ensures definitive cure 1.

Monitoring after RAI:

• Assess free T4 and total T3 within 1-2 months 1
• If still thyrotoxic, continue monitoring every 4-6 weeks 1
• TSH remains suppressed for ≥1 month after hyperthyroidism resolves—interpret cautiously with free T4/T3 1
• Retreat with RAI if minimal response at 3 months or persistent hyperthyroidism at 6 months 1

Absolute contraindications to RAI:

• Pregnancy or lactation 1
• Coexisting or suspected thyroid cancer 1
• Inability to comply with radiation safety guidelines 1
• Planning pregnancy within 4-6 months 1

Critical caveat: RAI may worsen Graves' ophthalmopathy, especially in smokers—consider corticosteroid prophylaxis in these patients 2.

Surgical Thyroidectomy

Preparation for surgery:

• Render patient euthyroid with methimazole first 1
• Add potassium iodide in immediate preoperative period 1
• In exceptional urgent circumstances when patient cannot be made euthyroid, use beta-blockade plus potassium iodide with experienced surgeon/anesthesiologist 1

Procedure: Near-total or total thyroidectomy is preferred to minimize recurrence 1.

Refer to high-volume thyroid surgeon to minimize complications 1.

Postoperative management:

• Stop ATDs at time of surgery; wean beta-blockers postoperatively 1
• Monitor serum calcium or intact PTH; supplement with calcium/calcitriol as needed 1
• Start levothyroxine at 0.8 μg/lb (1.7 μg/kg) daily 1
• Check TSH at 6-8 weeks 1

Surgical complications (1-5% risk): hypoparathyroidism and recurrent laryngeal nerve paralysis 2.

Relative contraindications:

• Significant cardiopulmonary disease or debilitating comorbidity 1
• Pregnancy (avoid first and third trimesters; if necessary, perform in second trimester with 4.5-5.5% preterm labor risk) 1

Toxic Multinodular Goiter and Toxic Adenoma

Similar principles apply with key differences:

• Beta-blockers before RAI for patients >60 years, cardiovascular disease, or severe hyperthyroidism 1
• Consider methimazole pretreatment in these high-risk patients (one guideline author dissented, favoring beta-blockers alone) 1
• Young/middle-aged patients generally need only beta-blockers, not methimazole pretreatment 1

Long-Term Follow-Up

After achieving euthyroidism with any modality, lifelong annual thyroid function testing is recommended 1. Hypothyroidism commonly develops months to years after RAI or surgery, requiring thyroid hormone replacement adjustment.